nucleosid
play
promin
role
medicin
chemistri
one
cornerston
antivir
anticanc
structur
base
natur
occur
nucleosid
figur
abil
recogn
biolog
signific
enzym
result
even
minor
chang
nucleosid
scaffold
profound
result
activ
mani
approach
nucleosid
drug
design
evolv
year
rang
remov
rearrang
addit
function
group
atom
base
sugar
scaffold
chang
shape
andor
size
sugar
anoth
modif
introduc
antonin
erik
de
flexibl
sugar
effort
explor
much
sugar
necessari
recognit
activ
systemat
remov
andor
carbon
correspond
hydroxyl
group
ribos
sugar
led
acycl
subsequ
acycl
phosphon
class
sever
still
use
clinic
today
includ
well
acycl
phosphon
tenofovir
figur
due
inher
flexibl
tenofovir
demonstr
abil
overcom
point
mutat
relat
develop
drug
resist
retain
although
idea
flexibl
sugar
moieti
becam
commonplac
introduct
flexibl
heterocycl
purin
littl
done
regard
investig
flexibl
nucleobas
surpris
sinc
common
knowledg
heterocycl
base
critic
base
pair
base
stack
latter
reliant
upon
polar
aromat
surfac
base
effort
explor
concept
introduc
flexibl
heterocycl
base
develop
class
nucleosid
known
flexim
bicycl
purin
ring
split
two
compon
exampl
pyrimidin
imidazol
ring
remain
connect
singl
bond
exemplifi
figur
allow
rotat
two
piec
still
retain
aromat
system
function
group
need
recognit
biolog
initi
hypothes
increas
flexibl
reposit
would
provid
flexim
advantag
possibl
rigid
nucleobas
exampl
inher
flexibl
allow
nucleosid
abil
rotat
reposit
bind
site
particularli
face
electron
steric
interfer
sinc
point
mutat
typic
involv
sort
amino
acid
chang
also
hypothes
would
allow
flexim
adjust
engag
secondari
amino
acid
residu
previous
involv
mechan
action
would
turn
allow
retain
activ
someth
rigid
analogu
would
abl
addit
flexibl
might
also
lead
increas
bind
affin
sinc
flexim
could
sampl
bind
site
find
favor
interact
addit
possibl
mutual
induc
fit
model
bind
site
ligand
might
lead
two
work
togeth
danc
partner
find
bestlowest
energi
conform
final
also
hypothes
flexim
could
chang
conform
might
abl
recogn
enzym
would
necessarili
interact
might
abl
mimic
differ
nucleosid
view
flexim
molecular
chameleon
chameleon
adapt
surround
order
surviv
flexim
would
also
adapt
confront
steric
electron
clash
bind
site
target
first
distal
flexim
develop
obtain
via
ring
open
reaction
seri
tricycl
treat
thiopheneexpand
tricycl
nucleosid
raney
nickel
sulfur
spacer
ring
remov
leav
two
heterocycl
free
rotat
remain
bond
middl
ring
figur
design
distal
flexim
base
similar
name
nelson
leonard
benzylexpand
purin
inspir
tricycl
nucleosid
synthesi
prove
quit
challeng
step
averag
achiev
distal
problem
yet
fulli
overcom
despit
number
attempt
optim
contrast
second
seri
denot
proxim
flexim
much
facil
achiev
sinc
requisit
substitut
pattern
two
heterocycl
piec
need
metal
catalyz
cross
coupl
method
allow
use
still
suzuki
organometal
coupl
reaction
depict
figur
first
set
compound
hand
screen
sadenosylhomocystein
hydrolas
sahas
enzym
target
focus
time
inhibit
sahas
lead
incomplet
biolog
methyl
util
sadenosylmethionin
sam
methyl
exampl
cap
structur
mrna
virus
parasit
particular
necessarili
possess
methyl
critic
stabil
recognit
accomplish
methyltransferas
mtase
util
sam
methyl
donor
occur
sam
convert
sadenosylhomocystein
sah
shown
figur
sahas
inhibit
lead
buildup
sah
turn
inhibit
methyltransferas
subsequ
lead
incomplet
translat
result
inhibit
sahas
indirectli
mtase
import
target
antivir
antiparasit
interestingli
preliminari
comput
result
show
distal
guanosin
flexim
flexg
figur
predict
favor
bind
energi
sahas
adenosin
analogu
flexa
figur
compound
made
actual
test
flexg
prove
inhibitor
knowledg
first
report
guanosin
nucleosid
inhibit
adenosinemetabol
enzym
addit
comput
result
bind
site
sahas
reveal
curv
synlik
conform
flexim
figur
seem
first
glanc
unlik
sinc
nucleosid
bulki
substitu
often
prefer
resid
favor
anti
upon
closer
examin
howev
becam
clear
flexibl
base
flexim
abl
form
intramolecular
hydrogen
bond
carbonyl
pyrimidin
sugar
ring
figur
addit
turn
swung
amino
group
flexg
area
bind
site
amino
group
adenosin
typic
essenti
creat
adenosin
mimic
would
explain
abil
flexg
act
sahas
effort
explor
interest
phenomenon
undertook
nmr
studi
collabor
plavec
et
result
show
solut
flexim
inde
prefer
expect
anti
conform
howev
enzym
syn
conform
domin
figur
lend
support
hypothesi
enzym
flexnucleosid
act
danc
partner
enzym
direct
influenc
conform
flexim
part
project
initi
collabor
laboratori
found
involv
investig
gdplfucos
pyrophosphorylas
gfpp
gfpp
enzym
involv
format
util
number
fucosemetabol
enzym
produc
two
separ
distinctli
differ
de
novo
pathway
gdplmannos
well
character
howev
salvag
pathway
via
gtp
poorli
understood
figur
moreov
littl
known
gfpp
littl
sequenc
ident
common
nucleotid
metabol
enzym
prefer
guanosin
analogu
substrat
effort
character
substrat
requir
intrigu
enzym
perform
extens
sar
studi
use
wide
varieti
differ
modifi
carbohydr
furanos
heterocycl
variou
surpris
flexgtp
prefer
twice
much
natur
substrat
gtp
indic
discrimin
factor
shown
tabl
effort
identifi
residu
respons
phenomenon
seri
mutat
strain
construct
result
show
mutant
lysin
mutat
alanin
flexgtp
recogn
mutant
gtp
longer
recogn
figur
amino
acid
four
residu
apart
flexgtp
abil
readjust
reposit
allow
engag
secondari
amino
acid
residu
previous
involv
mechan
action
order
stay
activ
addit
also
led
signific
increas
affin
therebi
confirm
two
initi
return
origin
focu
sahas
decid
explor
seri
carbocycl
flexim
potenti
antiparasit
agent
parasit
reli
heavili
methyl
cap
four
structur
end
mrna
stabil
replic
thu
incomplet
methyl
lead
disrupt
transcript
methyl
accomplish
variou
mtase
thu
inhibit
sahas
previous
mention
inhibit
methyl
therebi
disrupt
parasit
replic
regard
carbocycl
adenosin
nucleosid
known
best
sahas
inhibitor
thu
synthesi
seri
carbocycl
flexim
pursu
figur
first
seri
pursu
focus
differ
connect
base
moieti
connect
via
pyrimidin
ring
fivememb
ring
appendag
figur
yield
revers
inspir
chang
connect
came
nucleosid
analogu
first
publish
herdewijn
et
show
impress
activ
herp
simplex
viru
varicella
zoster
viru
vzv
initi
thought
revers
connect
might
also
lead
inhibit
purin
pyrimidin
metabol
enzym
sinc
consid
pyrimidin
glycosyl
purin
interestingli
revers
flexim
prove
activ
adenosin
deaminas
ada
act
product
inhibitor
forward
analogu
fail
show
real
activ
also
synthes
flex
borchardt
truncat
npc
shown
figur
comput
predict
better
binder
sahas
parent
unpublish
data
shown
figur
abil
sampl
bind
site
may
lead
better
bind
biolog
activ
amino
group
group
posit
ident
bind
site
howev
imidazol
ring
flexanalogu
abl
explor
new
area
bind
site
interact
truncat
origin
pursu
due
activ
ebola
unfortun
never
made
past
preliminari
anim
point
clear
time
move
next
level
realli
test
limit
flexim
concept
thank
grant
nation
institut
health
abl
pursu
applic
flexim
approach
modifi
sugar
found
sever
fdaapprov
nucleosid
therapeut
first
seri
design
figur
base
modif
found
sofosbuvir
mef
meoh
given
excit
potent
activ
unfortun
rout
realiz
analogu
extrem
step
overal
yield
futur
therapeut
despit
low
yield
abl
obtain
enough
make
mcguigan
test
result
unpublish
hcv
replicon
assay
moder
figur
notabl
howev
toxic
note
level
test
presenc
protid
moieti
increas
activ
albeit
slightli
tediou
lowyield
rout
previou
seri
second
seri
select
base
facil
synthet
rout
avail
appli
acycl
sugar
found
acyclovir
flexbas
approach
seri
acycl
flexim
made
figur
acyclovir
fdaapprov
drug
treat
also
recent
shown
activ
broad
screen
test
compound
show
activ
human
coronavirus
includ
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
quit
unexpect
due
lack
nucleosid
point
demonstr
anticoronaviru
activ
previou
lack
activ
nucleosid
analogu
attribut
uniqu
exonucleas
util
coronavirus
recogn
nucleosid
analogu
excis
importantli
acyclovir
exhibit
activ
sar
mer
thu
clear
flex
approach
respons
potent
activ
observ
anticip
compound
would
act
chain
termin
given
known
moa
compound
includ
triphosph
figur
screen
mer
sar
polymeras
interestingli
triphosph
incorpor
nascent
rna
strand
inhibit
mer
rnadepend
rna
polymeras
rdrp
correspond
sar
rdrp
unpublish
data
addit
studi
current
underway
fulli
character
differ
well
elucid
exactli
compound
work
coronavirus
addit
polymeras
studi
flexnucleosidestid
also
screen
panel
viral
human
mtase
surprisingli
flexim
exhibit
potent
activ
low
zikv
denv
rsv
mer
correspond
human
mtase
manuscript
prepar
select
cours
critic
ensur
safe
effect
therapeut
result
highli
promis
recent
investig
compound
also
reveal
potent
activ
ebola
ebov
sudan
well
dengu
denv
yellow
fever
yfv
zika
zikv
virus
unpublish
data
howev
result
report
elsewher
complet
seri
pursuit
flexim
limit
initi
paper
sever
research
adopt
flexim
approach
recent
pochet
et
al
util
enzymat
transglycosyl
synthet
rout
realiz
seri
imidazolesubstitut
flexim
scheme
use
purin
nucleosid
phosphorylas
pnp
nucleosid
ndeoxyribosyltransferas
ndt
base
thymidin
readili
switch
wide
varieti
arylsubstitut
imidazol
prepar
use
suzukimiyaura
crosscoupl
find
reveal
reaction
went
good
yield
enzym
recogn
flexim
although
ndt
prove
accept
two
hudson
et
al
publish
paper
click
flexim
util
popular
coppercatalyz
azidealkyn
huisgen
cycloaddit
reaction
shown
scheme
employ
sugar
group
abl
coupl
cytosin
gener
seri
flexim
scheme
also
studi
compound
conform
spectroscop
abl
show
diamino
analogu
display
characterist
deep
purpl
fluoresc
someth
could
exploit
variou
addit
confirm
previou
studi
discuss
show
flexim
prefer
coplanar
koszytkowskastawinska
et
al
also
synthes
triazol
flexim
util
bannert
cascad
involv
sigmatrop
rearrang
scheme
howev
analogu
contain
methylen
group
azid
pyrimidin
moieti
scheme
synthes
sever
ribos
analogu
well
acycl
phosphon
analogu
howev
biolog
activ
includ
final
peyrott
et
al
incorpor
triazol
flexim
scheme
place
pyrimidin
found
natur
purin
base
flexim
group
employ
wide
rang
substitut
interestingli
modest
activ
note
compound
cytosol
ii
enzym
involv
regul
purin
nucleotid
pool
also
link
caus
resist
cancer
serendipit
approach
robin
et
al
discov
uniqu
rout
realiz
oxadiazolesubstitut
imidazol
flexim
mean
unexpect
ring
open
adenosin
noxid
nucleosid
occur
treat
variou
anhydrid
scheme
rearrang
uncommon
noxid
nucleosid
typic
result
adenosin
split
base
found
although
interest
result
oxadizaol
ring
lack
critic
hydrogen
bond
element
found
purin
ring
system
need
recognit
base
pair
therebi
limit
util
part
studi
gundersen
et
al
seri
flexim
employ
benzen
ring
instead
typic
ribos
sugar
construct
figur
previou
studi
group
purin
substitut
benzen
ring
led
interest
activ
thu
provid
preced
pursu
analogu
one
major
differ
analogu
connect
benzen
ring
flex
base
involv
methylen
group
typic
cn
glycosid
bond
figur
notabl
one
compound
exhibit
excel
activ
mycobacterium
tuberculosi
final
bardon
wetmor
carri
extens
comput
studi
use
densiti
function
theori
effort
investig
number
factor
relat
flexim
structur
studi
includ
assess
barrier
rotat
base
pair
properti
well
variou
connect
result
show
littl
barrier
rotat
comput
barrier
less
inclus
ribos
sugar
lower
even
term
base
pair
flexim
pair
correctli
maintain
normal
purin
hydrogen
bond
pattern
prefer
connect
vari
base
presenc
sugar
ring
figur
without
sugar
present
distal
conform
possess
lowest
energi
conform
sugar
proxim
moreov
two
base
compon
prefer
stay
planar
case
particularli
proxim
analogu
howev
distal
tend
prefer
perpendicular
conform
base
specif
summari
result
outlin
herein
underlin
grow
import
flex
approach
target
virus
biolog
signific
enzym
import
keep
mind
variou
flexim
describ
herein
recogn
everi
enzym
investig
work
way
variou
enzym
inhibit
recogn
speak
theori
flexim
enzym
work
danc
partner
lead
select
rather
indiscrimin
activ
potenti
toxic
new
seri
pursu
studi
result
increas
inform
endless
possibl
uniqu
nucleosid
result
look
forward
explor
new
analogu
report
properti
activ
futur
